{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:41:51Z","timestamp":1790649711563,"version":"4.1.0"},"reference-count":8,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,4,25]]},"abstract":"<jats:p>A 70-year-old patient with known hereditary haemorrhagictelangiectasia (HHT) was seen regularly in our outpatient clinic. He underwent multiple therapeutical interventions, including both surgical and medical, for the treatment of recurrent epistaxis without sustained success. Due to a concurrent diagnosis of idiopathic pulmonary fibrosis, treatment with the tyrosine kinase inhibitor nintedanib was initiated, after which point the patient reported a dramatic and unanticipated improvement in his epistaxis and skin telangiectasia. On the basis of this case report, we propose that nintedanib may be a potential treatment option for refractory epistaxis in HHT.<\/jats:p>","DOI":"10.1136\/bcr-2017-219393","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T09:00:07Z","timestamp":1498467607000},"page":"bcr-2017-219393","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia"],"prefix":"10.1136","volume":"2017","author":[{"given":"Evelin","family":"Kovacs-Sipos","sequence":"first","affiliation":[{"name":"Department of ENT Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holzmann","sequence":"additional","affiliation":[{"name":"Department of ENT Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scherer","sequence":"additional","affiliation":[{"name":"Pulmonary Center, Hirslanden Klinik, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Soyka","sequence":"additional","affiliation":[{"name":"Department of ENT Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S45295"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200908-1284OC"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5045\/br.2014.49.3.192","article-title":"Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab","volume":"49","author":"Wee","year":"2014","journal-title":"Blood Res"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.5","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1022693"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.6","first-page":"101","article-title":"Ofev (Nintedanib): First tyrosine kinase Inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/ajg.2010.155","article-title":"A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab","volume":"105","author":"Papa","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2025082800592132000_2017.jun26_1.bcr-2017-219393.8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4081\/hr.2013.e7","article-title":"Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome","volume":"5","author":"Sartor","year":"2013","journal-title":"Hematol Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-219393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:59:29Z","timestamp":1756367969000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-219393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":8,"alternative-id":["10.1136\/bcr-2017-219393"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-219393","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]}}}